This webinar will provide a platform to learn about the findings from the Longevity HCV and TB end users and healthcare providers/policy makers surveys, and for community members, especially marginalized populations across the world, to engage with the researchers developing these Long-Acting Therapies.
The Research Matters Advocacy Toolkit is a vital resource for researchers committed to advancing health equity and biomedical advocacy.
What does TAG's work look like in action? Here we step into a day in the life of our TB program co-directors, Mike Frick and Lindsay McKenna, to see how their advocacy for better TB research and policy — made possible by your support — are driving meaningful change to save lives and empower communities affected by TB.
TAG’s Magic Mountains of Debt: Sovereign Debt Crises as Critical Barriers to Ending TB and Investing in Sustainable Development Goals analyzes the impact of sovereign debt in depressing investments in TB programs, services, and R&D in high-TB burden nations.
TAG, APCASO, and Diagnostics Equity Consortium (DEC) hosted a two-part webinar series exploring the evolving TB diagnostic landscape and strategies to increase TB testing coverage, with a specific focus on the South-East Asia and Western-Pacific regions.
TAG is one of the endorsers of this Diagnostic Equity Consortium statement and call to action advocating for scaling up access to diagnostics to address the deadly gaps in TB testing.
Survey now extended until April 24! TAG, with support from Wellcome, is conducting a scoping exercise of community partners and interventions to support new TB vaccine readiness.
Learn more about the latest TB vaccine research here: TAG’s TB Vaccines Pipeline Report Learn more about the Global TB CAB here: 10-Year TB CAB Anniversary Evaluation Report and Podcast Learn more about TAG’s work on pre-approval access…
This policy brief describes the crucial role NIH plays in supporting research on new products to prevent, diagnose, and cure TB. This research is especially important at a time when new forms of drug resistance are emerging globally, and rates of TB are rising in the U.S. With continued and increased funding, NIH can protect Americans from the growing threat of TB at home and abroad.
The new 2025 update of An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis lays out what community advocates need to know about WHO-recommended regimens for drug-resistant TB.